Multicancer tests: Can we screen without knowing the outcome?
An FDA panel recently reviewed multicancer early detection tests, highlighting significant data gaps regarding their clinical utility and impact on patient outcomes.
Olaparib: Why HRD in breast and ovarian cancer goes beyond BRCA
Olaparib demonstrated activity in HR-deficient metastatic triple-negative breast cancer and platinum-sensitive relapsed ovarian cancer without germline BRCA1/2 mutations.
Lung cancer in never smokers: The 60x risk factor you might be missing
A specific EGFR variant significantly increases lung cancer risk in individuals who have never smoked, challenging traditional views on lung cancer etiology. This genetic predisposition highlights a critical, often overlooked, pathway to disease development.
Brain metastases: Why less radiation, more often, improves outcomes
Why are we still treating cancer prevention as adjunctive care?
Chemo hair loss: Why some patients feel it more deeply
Breast cancer home injections: Convenient for patients, complex for insurers
Multicancer early detection: Can we screen for what we can't treat?
Salivary gland cancer: Is HER2-low the new HER2-positive?
Liver disease: Is coffee a daily dose of prevention?
Regular coffee consumption is associated with a reduced risk of liver disease, with a specific daily intake range appearing most beneficial. The protective effect extends across various liver conditions, including fibrosis and cirrhosis.
MASH: Why diabetes management now demands a liver-first approach?
Emerging liver-directed approaches for moderate to advanced MASH are reshaping treatment paradigms, with significant implications for diabetes specialists managing metabolic dysfunction.
Seladelpar and Elafibranor: The Second-Line Options for PBC After Ursodeoxycholic Acid Fails
Seladelpar and elafibranor offer new therapeutic avenues for primary biliary cholangitis patients with inadequate response to ursodeoxycholic acid.
Chronic hepatitis B: Is PD-1 blockade the key to T-cell revival?
ACLF: Why G-CSF works for some, but fails others
Pruritus in primary biliary cholangitis: the symptom that drives quality of life
Cholangiocarcinoma Surveillance: What Interval, What Modality in PSC?
Seladelpar and elafibranor: second-line options for PBC
Why primary sclerosing cholangitis remains a therapeutic graveyard
Endocarditis: Why fixed-dose ampicillin often misses the mark
A personalized antibiotic strategy, guided by therapeutic drug monitoring, optimizes ampicillin regimens in enterococcal bloodstream infections and endocarditis.
Peripheral arterial disease: Why early detection still eludes us
Peripheral arterial disease often goes undiagnosed until advanced stages, leading to preventable complications. Early detection is critical for improving patient outcomes.
Tactical athletes need more than a sports physical
New recommendations address cardiovascular screening and management for tactical athletes, focusing on unique physiological demands and risk factors in this population.
Hypertension: Do shorter wall squats work as well for older women?
LAA occlusion: Less bleeding, but is stroke risk truly equal?
Evolocumab: Is LDL-C reduction finally translating to lives saved?
GLP-1s: Is eligibility missing half your high-risk patients?
Beyond diagnosis: ECG waveforms predict MI-E treatment response
Rethinking xylitol: Is this 'healthy' sugar substitute a cardiac threat?
The 2026 ADA/EASD consensus: Why early SGLT2/GLP-1 works
The 2026 ADA and EASD consensus advocates early SGLT2 inhibitor or GLP-1-based therapy, potentially from diagnosis, and makes weight a formal treatment target.
Survodutide: Is 9.8% weight loss enough for its GI cost?
SYNCHRONIZE-2 in NEJM: survodutide 6.0 mg cut weight 9.8% versus 3.9% on placebo over 76 weeks in type 2 diabetes, but about 1 in 4 stopped treatment.
Rotavirus vaccine and T1D: Is an 11% rise cause for alarm?
Type 1 diabetes incidence in Norwegian children rose 11% after rotavirus vaccination began, but similar rises followed unrelated vaccine changes.
Marathon running with type 1 diabetes: Is it finally safe?
Amylin plus tirzepatide: Is 23% weight loss the new benchmark?
Low-carb diets in kids with type 1 diabetes: safe, but not standard?
Type 1 diabetes screening: Why one protocol worked across 8 nations
CBL-514: Is visceral fat reduction the real story?
Bariatric surgery: The hidden hernia risk you're missing
Brexpiprazole for Alzheimer's agitation: Antidepressants don't change efficacy
A post hoc analysis found brexpiprazole reduced agitation in Alzheimer's dementia, with similar efficacy regardless of concomitant antidepressant use.
Epilepsy: Is art the missing piece in holistic patient care?
A new exhibit showcases artists living with epilepsy, aiming to reframe public perception of the condition beyond its clinical manifestations.
Can mice learn to control their own brains? A new neurofeedback system
A real-time closed-loop neurofeedback system allowed mice to modulate cortical activity and movement, adapting to rule changes for reward acquisition.
Fibromyalgia: Is the pain real if the tissue damage isn't?
Parkinson's cognitive decline: Is Juvmo the answer we overlooked?
Routine childhood vaccines: Less coverage means more than just infections
Lifelong odor sensitivity: What early exposure means for your patients?
Tau: Why its 'knockout' effect is a clue to Alzheimer's
Spike sorting: Is your 'black box' holding back neural insights?
R-CHOP has been standard of care for 20 years. frontMIND may be the beginning of the end
An epidemiological shift in T2D is reshaping drug development and market access for oncology and metabolic portfolios.
The most resistant cancer is finally responding, and the pipeline is accelerating
Lecanemab and donanemab are approved. The harder question is who gets them and how
Label expansion triples the eligible population and the infrastructure race begins
LeukemiaRusfertide and hepcidin mimetics: a different way to control erythrocytosis
Get the full storyHaematocrit targets: Is 45% still the right threshold for phlebotomy?
Get the full storyWhy molecular response in polycythemia vera remains an elusive endpoint
Get the full storyPNH: Beyond Eculizumab, How Proximal Inhibition Reshaped Treatment Goals
Get the full storyWhen complement inhibitors fail: Recognizing breakthrough haemolysis
Get the full storyOral factor B inhibition: a new path for PNH management?
Get the full storyMyelofibrosis: Why transplant timing dictates survival, not just symptoms
Get the full storyChoosing a JAK Inhibitor in Myelofibrosis: Beyond Ruxolitinib
Get the full storyMomelotinib and anaemia in myelofibrosis: a new calculus for treatment?
Get the full storyGene therapy for thalassemia: Approval is one hurdle, access is the next
Get the full story
Idiopathic Pulmonary Fibrosis
Clostridioides difficile
AdvertisementAdvertisementAdvertisement
• Oct 17 – 20Joint ACTRIMS-ECTRIMS 2026 • Toronto, CA 
• Oct 21 – 23ESMO 2026 • Madrid, ES • Oct 23 – 27ACR 2026 • Orlando, US 
• Nov 6 – 11AHA 2026 • Chicago, US • Nov 6 – 9ASH 2026 • New Orleans, US • Dec 12 – 15ACC.27 Together With WCC • Houston, US • Apr 10 – 12LIVEUEG Week 2026 • Barcelona, ES • Oct 17 – 20Joint ACTRIMS-ECTRIMS 2026 • Toronto, CA • Oct 21 – 23ESMO 2026 • Madrid, ES • Oct 23 – 27ACR 2026 • Orlando, US • Nov 6 – 11AHA 2026 • Chicago, US • Nov 6 – 9ASH 2026 • New Orleans, US • Dec 12 – 15ACC.27 Together With WCC • Houston, US • Apr 10 – 12
Advertisement
BarcelonaOct 17 – 20 2026Get on-site reporting the moment it publishes.
BarcelonaAttending UEG Week 2026?
Get our free prep guide: key sessions by day, satellite symposia listings, and recommended spots near the venue.
Free. No spam. Unsubscribe anytime.
